Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by State Street Corp

State Street Corp lifted its holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) by 3.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,000,998 shares of the biopharmaceutical company’s stock after acquiring an additional 33,496 shares during the quarter. State Street Corp owned 1.53% of Regulus Therapeutics worth $1,572,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in RGLS. Creative Planning acquired a new stake in Regulus Therapeutics during the 3rd quarter worth about $26,000. SG Americas Securities LLC purchased a new position in Regulus Therapeutics during the third quarter valued at approximately $33,000. Rhumbline Advisers acquired a new position in Regulus Therapeutics in the second quarter valued at approximately $136,000. Tyche Wealth Partners LLC boosted its position in Regulus Therapeutics by 920.6% in the 3rd quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock worth $167,000 after purchasing an additional 95,694 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Regulus Therapeutics by 56.4% during the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 42,600 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Stock Up 5.3 %

Shares of NASDAQ RGLS opened at $1.58 on Thursday. The firm has a market cap of $103.49 million, a price-to-earnings ratio of -1.48 and a beta of 1.61. The company’s 50-day simple moving average is $1.54 and its 200-day simple moving average is $1.64. Regulus Therapeutics Inc. has a 52-week low of $1.08 and a 52-week high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Equities research analysts anticipate that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on RGLS. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a report on Monday, November 11th. StockNews.com upgraded Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.80.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.